

Integrium, LLC Executives to Attend 10th Annual LD Micro Main Event in Los Angeles, CA

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be attending the 10th Annual LD Micro Main Event in Los Angeles, CA starting on the evening of December 4th through 7th, 2017. The conference brings together micro-cap companies looking to collaborate on ideas and recent findings in the industry, as well as old and new companies looking to strategize.

Integrium Executives value the opportunity that is provided at the LD Micro event because of the exposure they have to various micro-cap companies that have joined the group. With access to keynote speakers, panel discussions, and high-level presentations, the event is the perfect opportunity for Integrium to make and advance relationships within the micro-cap community.



Specializing in helping micro-cap biotechs, Integrium helps their clients attain clinical data so they can raise their next round of capital. There is an increasing amount of biotechs wanting to work with a smaller, more unique CRO because of the hands-on relationships that will be built.

Biotechs, specifically micro-caps, are looking to right-size and choose Integrium because they have a big bandwidth, exclusive business model, and access to key industry leaders. Integrium can provide clinical experience to biotechs that need assistance, guidance, and advice throughout their study start up process.



Integrium's main attributes:

- Almost 90% of Integrium's clients are either:
 - Referred by existing clients.
 - Already have worked with a larger CRO than Integrium and are looking for a compatible size.
- Allow access to the Principals of the company that have over 20 years of clinical trial experience.
- Ability to enroll on time and on-budget, whether healthy or non-healthy patients.
- Anticipate any problems before they occur by working with Integrium

Principals.

- Provide capital efficient prices and quick turnaround time.

Integrium will be available for meetings throughout the event and encourages guests reach out to Emily MacHale, Associate Director of Marketing & Research at Emily.MacHale@integrium.com for any meeting requests.



About Integrium

Founded in 1998 by visionary clinical research thought leaders, Integrium is a full-service Phase I-IV clinical CRO that specializes in a wide range of therapeutic areas. Integrium plays a key role in furthering new medical advancements by helping pharmaceutical companies design and execute clinical studies, ensuring they achieve their objectives on time, on budget, and with expected quality.

Integrium helps micro-cap, small-cap, and privately-held biotechs within the innovator and generic space attain clinical data so they can raise the next round of capital. Integrium's areas of therapeutic focus include Cardiovascular, Metabolic, Regenerative Medicine, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule II drugs and Oncology.

Check out our new website!

www.integrium.com

To learn more about Integrium, contact:

Emily MacHale

Associate Director of Marketing & Research

Emily.MacHale@Integrium.com

908-375-2009

